Physician profile
Tony Luongo
NPI 1164520417
$264,666.79
in general payments reported to CMS, 2019-2025
41 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88K · 2020: $37K · 2021: $38K · 2022: $30K · 2023: $9,698 · 2024: $42K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $20K · Travel and Lodging: $7,581 · Food and Beverage: $2,732 · Honoraria: $400 · Education: $91.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,935.00 |
| Consulting Fee | $19,752.75 |
| Travel and Lodging | $7,580.78 |
| Food and Beverage | $2,732.15 |
| Honoraria | $400.00 |
| Education | $91.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $108,195.75 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Astellas Pharma US INC | $80,809.15 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $32,600.52 | 2019-2025 | |
| Medtronic, INC. | $10,633.71 | 2022-2024 | |
| Myovant Sciences INC. | $10,615.84 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $5,720.25 | 2019-2024 | Bard Urinary Drainage Bag |
| Bard Peripheral Vascular, INC. | $5,350.00 | 2019-2023 | |
| Gyrus Acmi, INC. | $3,050.00 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,841.41 | 2019 | |
| Olympus Medical Systems Corporation | $1,620.00 | 2023 | Oes Choledochofiberscope |
| Ambu A/S | $750.00 | 2024 | |
| Sun Pharmaceutical Industries INC. | $500.00 | 2021 | |
| Tersera Therapeutics LLC | $487.00 | 2022-2023 | |
| Genzyme Corporation | $350.00 | 2020 | |
| Becton, Dickinson and Company | $340.00 | 2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $178.01 | 2024-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $143.47 | 2019-2020 | |
| Urogen Pharma, INC. | $139.82 | 2021-2023 | Jelmyto |
| 180 Medical, INC. | $137.78 | 2023-2024 | Gentlecath, Speedicath |
| Telix Pharmaceuticals | $129.52 | 2023-2025 | Illuccix |
| Antares Pharma, INC. | $112.34 | 2019-2022 | |
| Boston Scientific Corporation | $106.79 | 2022-2025 | Rezum Generator, Ams 700 |
| Merck Sharp & Dohme LLC | $104.03 | 2024 | Keytruda, Lynparza |
| Blue Earth Diagnostics | $94.16 | 2019 | |
| Progenics Pharmaceuticals, INC. | $83.46 | 2021-2023 | Pylarify |
| Abbvie INC. | $77.32 | 2019-2023 | |
| Coloplast Corp | $71.97 | 2019-2025 | |
| Immunitybio, INC. | $62.77 | 2024 | |
| Convatec INC. | $48.83 | 2024 | |
| Urovant Sciences INC | $42.54 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $41.34 | 2022 | |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Sumitomo Pharma America, INC. | $38.33 | 2023 | Gemtesa |
| Teleflex LLC | $37.45 | 2024 | Urolift |
| Tolmar, INC. | $26.68 | 2024 | |
| Metuchen Pharmaceuticals | $20.30 | 2019 | |
| Rochester Medical Corporation | $18.71 | 2022 | |
| Allergan, INC. | $17.20 | 2019 | |
| Medtronic USA, INC. | $15.36 | 2019 | |
| Myriad Genetic Laboratories, INC. | $14.98 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Luongo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.